Form 8-K

8-K — Alpha Teknova, Inc.

Accession: 0001193125-26-335059

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001850902

SIC: 2835 (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tkno-20260805.htm (Primary)

EX-99.1 (tkno-ex99_1.htm)

GRAPHIC (img201297901_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: tkno-20260805.htm · Sequence: 1

8-K

0001850902false00018509022026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2026

Alpha Teknova, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-40538

94-3368109

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2451 Bert Drive

Hollister, California

95023

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 831 637-1100

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

TKNO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2026, Alpha Teknova, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release issued by Alpha Teknova, Inc., dated August 5, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALPHA TEKNOVA, INC.

Date:

August 5, 2026

By:

/s/ Stephen Gunstream

Stephen Gunstream

President and Chief Executive Officer

EX-99.1

Filename: tkno-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Teknova Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year

Company raises 2026 revenue guidance to $45-47 million

Launched proprietary AI-powered Build-TekTM custom order configurator, giving developers a faster path from preclinical to clinical manufacturing

HOLLISTER, Calif., August 5, 2026 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026.

"We delivered more than $12 million in quarterly revenue for the first time in Teknova's history, with growth across nearly all of the end markets we serve," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "These results demonstrate the impact of the investments we've made in our commercial organization, state-of-the-art facilities, and manufacturing systems, and strengthen our confidence in our ability to deliver long-term, sustainable growth as the biotech market continues to recover."

Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered excellent financial results in the second quarter 2026 compared to 2025, including 18% revenue growth and a significant improvement in Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $45-47 million and adjusting down our expectations for full-year Free Cash Outflow to less than $8 million,” he explained.

Corporate and Financial Updates

•

Second quarter 2026 total revenue of $12.2 million, up 18% compared to $10.3 million for the second quarter 2025

•

Total cash and short-term investments were $17.4 million and total borrowings were $13.2 million at the end of the second quarter 2026

•

Following a second quarter beta release, the Company launched Build-Tek™, the AI-powered evolution of its proprietary custom configurator first introduced in 2024, now enabling therapeutic and diagnostic developers to build complex custom products in just minutes

Revenue for the Second Quarter 2026

For the Three Months Ended June 30,

For the Six Months Ended June 30,

(Dollars in thousands)

2026

2025

2026

2025

Lab Essentials

9,184

7,792

17,579

15,909

Clinical Solutions

2,428

2,060

4,573

3,222

Other

573

435

1,110

951

Total revenue

12,185

10,287

23,262

20,082

Second Quarter 2026 Financial Results

Total revenue for the second quarter 2026 was $12.2 million, up 18% compared to $10.3 million in the second quarter 2025. Lab Essentials revenue was $9.2 million in the second quarter 2026, up 18% compared to $7.8 million in the second quarter 2025. Clinical Solutions revenue was $2.4 million in the second quarter 2026, up 18% compared to $2.1 million in the second quarter 2025.

Gross profit for the second quarter 2026 was $4.9 million, compared to $4.0 million in the second quarter 2025. Gross margin for the second quarter 2026 was 40.1%, compared to 38.7% in the second quarter 2025. The increase in gross margin was primarily driven by higher revenue, partially offset by higher fixed cost absorption into cost of goods sold from faster finished goods inventory turns. This compares to the same period in the prior year that had benefited from unusually favorable manufacturing efficiency gains.

Operating expenses for the second quarter 2026 were $7.8 million, compared to $7.4 million in the second quarter 2025. The increase was primarily driven by higher spending in sales and marketing, a result of higher headcount and increased marketing expenses, partially offset by lower general and administrative expenses attributable to lower stock-based compensation expense.

Net loss for the second quarter 2026 was $3.2 million, or negative $0.06 per diluted share, compared to $3.6 million, or negative $0.07 per diluted share, for the second quarter 2025. Adjusted EBITDA for the second quarter 2026 was negative $0.7 million, compared to negative $0.8 million for the second quarter 2025.

Cash used in operating activities for the second quarter 2026 was $0.5 million, compared to $2.1 million of cash used in operating activities for the second quarter 2025. Free Cash Outflow was $0.6 million for the second quarter 2026, compared to $2.3 million for the second quarter 2025.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Improves 2026 Outlook

Teknova raises its fiscal 2026 outlook for revenue and improves its outlook for Free Cash Outflow. The Company now anticipates total revenue of $45 million to $47 million for the fiscal year ending December 31, 2026 (“2026”). The Company also now expects Free Cash Outflow of less than $8 million for 2026.

Upcoming Investor Conference Attendance

Sidoti Microcap Conference (Virtual)

August 19-20, 2026

ROTH Healthcare Opportunities Conference (New York, NY)

September 29, 2026

Conference Call and Webcast

Teknova will host a webcast and conference call on Wednesday, August 5, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of

the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Non-GAAP Financial Measures

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).

Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.

Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws.

Investor Contact

Matt Lowell

Chief Financial Officer

matt.lowell@teknova.com

+1 831-637-1100

Media Contact

Jennifer Henry

Senior Vice President, Marketing

jenn.henry@teknova.com

+1 831-313-1259

ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

For the Three Months Ended June 30,

For the Six Months Ended June 30,

2026

2025

2026

2025

Revenue

12,185

10,287

23,262

20,082

Cost of sales

7,300

6,303

14,593

13,091

Gross profit

4,885

3,984

8,669

6,991

Operating expenses:

Research and development

554

581

1,163

1,133

Sales and marketing

2,122

1,573

4,250

3,213

General and administrative

4,812

4,929

9,870

10,421

Amortization of intangible assets

287

574

Total operating expenses

7,775

7,370

15,857

15,341

Loss from operations

(2,890

)

(3,386

)

(7,188

)

(8,350

)

Other (expenses) income, net

Interest expense, net

(252

)

(165

)

(471

)

(309

)

Other adjustment to loan exit fee

—

485

Other income

—

Total other (expenses) income, net

(250

)

(165

)

(460

)

176

Loss before income taxes

(3,140

)

(3,551

)

(7,648

)

(8,174

)

Provision for income taxes

Net loss

(3,170

)

(3,570

)

(7,725

)

(8,215

)

Net loss per share—basic and diluted

(0.06

)

(0.07

)

(0.14

)

(0.15

)

Weighted average shares used in computing net loss per share—basic and diluted

53,634,826

53,448,736

53,614,671

53,435,210

ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

As of June 30,

As of December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

6,004

5,912

Short-term investments, held-to-maturity

11,432

15,426

Accounts receivable, net

5,408

4,618

Inventories, net

6,911

7,054

Prepaid expenses and other current assets

1,069

1,501

Total current assets

30,824

34,511

Property, plant, and equipment, net

39,311

41,733

Operating right-of-use lease assets

13,247

14,112

Intangible assets, net

11,369

11,943

Other non-current assets

1,127

1,285

Total assets

95,878

103,584

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

1,438

1,378

Accrued liabilities

3,476

4,283

Current portion of operating lease liabilities

1,958

1,876

Total current liabilities

6,872

7,537

Deferred tax liabilities

956

879

Long-term debt, net

13,218

13,123

Long-term operating lease liabilities

12,232

13,270

Total liabilities

33,278

34,809

Stockholders’ equity:

Preferred stock

—

Common stock

Additional paid-in capital

206,114

204,564

Accumulated deficit

(143,515

)

(135,790

)

Total stockholders’ equity

62,600

68,775

Total liabilities and stockholders’ equity

95,878

103,584

ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

For the Three Months Ended June 30,

For the Six Months Ended June 30,

2026

2025

2026

2025

Operating activities:

Net loss

(3,170

)

(3,570

)

(7,725

)

(8,215

)

Adjustments to reconcile net loss to net cash used in operating activities:

Bad debt expense

)

Inventory reserve

412

488

825

925

Depreciation and amortization

1,593

1,590

3,169

3,170

Stock-based compensation

622

950

1,317

1,802

Deferred taxes

Accrued interest income on short-term investments

108

Amortization of discount on short-term investments

(58

)

(171

)

(145

)

(355

)

Amortization of debt financing costs

129

Other adjustment to loan exit fee

—

(485

)

Non-cash lease expense

Loss on disposal of property, plant, and equipment

Changes in operating assets and liabilities:

Accounts receivable

266

472

(795

)

(877

)

Inventories

(449

)

(1,525

)

(682

)

(1,734

)

Prepaid expenses and other current assets

155

(36

)

312

(40

)

Other non-current assets

(29

)

158

Accounts payable

(172

)

(360

)

158

380

Accrued liabilities

113

(135

)

(659

)

(1,152

)

Other

—

(10

)

Cash used in operating activities

(471

)

(2,101

)

(3,830

)

(6,204

)

Investing activities:

Purchases of short-term investments

(3,930

)

(7,765

)

(7,868

)

(9,735

)

Maturities of short-term investments

6,000

10,000

12,000

16,000

Purchases of property, plant, and equipment

(125

)

(207

)

(346

)

(413

)

Cash provided by investing activities

1,945

2,028

3,786

5,852

Financing activities:

Proceeds from long-term debt

—

1,110

Payment of exit fee costs

—

(1,110

)

Repayment of financed insurance premiums

—

(97

)

(56

)

Proceeds from exercise of stock options

170

179

Proceeds from issuance of common stock under employee stock purchase plan

Payment of debt issuance costs

—

(100

)

—

(100

)

Cash provided by (used in) financing activities

224

(28

)

136

(80

)

Change in cash and cash equivalents

1,698

(101

)

(432

)

Cash and cash equivalents at beginning of period

4,306

3,377

5,912

3,708

Cash and cash equivalents at end of period

6,004

3,276

6,004

3,276

ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

For the Three Months Ended June 30,

For the Six Months Ended June 30,

2026

2025

2026

2025

Net loss – as reported

(3,170

)

(3,570

)

(7,725

)

(8,215

)

Add back:

Interest expense, net

(252

)

(165

)

(471

)

(309

)

Provision for income taxes

Depreciation expense

1,306

1,303

2,595

2,596

Amortization of intangible assets

287

574

EBITDA

(1,295

)

(1,796

)

(4,008

)

(4,695

)

Other and non-recurring expenses:

Stock-based compensation expense

622

950

1,317

1,802

Other adjustment to loan exit fee

—

(485

)

Adjusted EBITDA

(673

)

(846

)

(2,691

)

(3,378

)

For the Three Months Ended June 30,

For the Six Months Ended June 30,

2026

2025

2026

2025

Cash used in operating activities

(471

)

(2,101

)

(3,830

)

(6,204

)

Purchases of property, plant, and equipment

(125

)

(207

)

(346

)

(413

)

Free Cash Flow

(596

)

(2,308

)

(4,176

)

(6,617

)

GRAPHIC

Filename: img201297901_0.jpg · Sequence: 3

Binary file (375444 bytes)

Download img201297901_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document And Entity Information

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity Registrant Name

Alpha Teknova, Inc.

Entity Central Index Key

0001850902

Entity Emerging Growth Company

true

Entity File Number

001-40538

Entity Incorporation, State or Country Code

Entity Tax Identification Number

94-3368109

Entity Address, Address Line One

2451 Bert Drive

Entity Address, City or Town

Hollister

Entity Address, State or Province

Entity Address, Postal Zip Code

95023

City Area Code

831

Local Phone Number

637-1100

Entity Information, Former Legal or Registered Name

N/A

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Ex Transition Period

false

Title of 12(b) Security

Common Stock, par value $0.00001 per share

Trading Symbol

TKNO

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration